Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1247 participants.

Also called NCT03706833

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,247 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03706833
Other papers using this trial's data
  • Impact of Residual Mitral Regurgitation and Gradient After M‑TEER: 1‑Year Outcomes From the CLASP IID Trial JACC. Cardiovascular imaging, 2026-07 DOI, PubMed 42233921

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Germany, Switzerland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03706833. Randomized; no masking; primary purpose treatment. Start 2018-11-30 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
Acronym
CLASP IID/IIF
Condition
Degenerative Mitral Valve Disease
Condition
Mitral Regurgitation
Condition
Mitral Insufficiency
Condition
Functional Mitral Regurgitation
Intervention (Device)
Edwards PASCAL System
Intervention (Device)
Abbott Mitraclip System
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct03706833
Content hash
b0e5ed8afc101b2187599f51e308f9a055319554b53fb43d27f5375c6d551011